Sign in

CIK 0001842295

  • Non-accelerated filer
  • Emerging growth company

Maze Therapeutics, Inc.

Sign in to watch
Ticker
MAZE
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
Phone
+1 650-850-5070
Business address
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO, CA, 94080
  1. 4 Planned sale CSBO sold 7,500 shares at $25.37 ($190,299)
  2. 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $29.46 ($441,904)
  3. 4 Planned sale SVP, Finance sold 2,500 shares at an average $29.44 ($73,611)
  4. 4 Planned sale CSBO sold 7,500 shares at an average $29.34 ($220,019)
  5. 4 Derivatives Options or other derivatives
  6. 3 Insider Initial Statement of Ownership
  7. 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $49.10 ($736,439)
  8. 4 Planned sale President, R&D & CMO sold 30,000 shares at an average $50.45 ($1,513,560)
  9. 4 Derivatives Options or other derivatives
  10. 4 Derivatives Options or other derivatives
  11. 4 Planned sale CSBO sold 7,500 shares at an average $45.43 ($340,723)
  12. 4 Derivatives Options or other derivatives
  13. 4 Planned sale SVP, Finance sold 5,000 shares at an average $45.20 ($226,011)
  14. 4 Derivatives Options or other derivatives
  15. 4 Planned sale President, R&D & CMO sold 15,000 shares at an average $46.02 ($690,334)
  16. 4 Planned sale SVP, Finance sold 5,000 shares at an average $46.04 ($230,219)
  17. 4 Planned sale CSBO sold 7,500 shares at an average $44.27 ($331,990)
  18. 4 Planned sale SVP, Finance sold 5,000 shares at $45.52 ($227,612)
  19. 4 Planned sale President, R&D & CMO sold 25,156 shares at $40.20 ($1,011,299)
  20. 4 Open-market sale Director sold 29,413 shares at an average $39.07 ($1,149,054)

Page 3 of 6 · 108 filings